Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.

Blood - 15 Sept 2004

Jiang Jingrui, Paez J Guillermo, Lee Jeffrey C, Bo Ronghai, Stone Richard M, DeAngelo Daniel J, Galinsky Ilene, Wolpin Brian M, Jonasova Anna, Herman Paula, Fox Edward A, Boggon Titus J, Eck Michael J, Weisberg Ellen, Griffin James D, Gilliland D Gary, Meyerson Matthew, Sellers William R

Abstract excerpt

The FLT3 receptor is activated by juxtamembrane insertion mutations and by activation loop point mutations in patients with acute myeloid leukemia (AML). In a systematic tyrosine kinase gene exon resequencing study, 21 of 24 FLT3 exons were sequenced in samples from 53 patients with AML, 9 patients with acute lymphoblastic leukemia (ALL), and 3 patients with myelodysplasia samples. Three patients had novel point...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme Activation
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hydrogen Bonding

Share to Interleukin-3

Share to Leukemia, Myeloid, Acute

Share to Proto-Oncogene Proteins

Share to Receptor Protein-Tyrosine Kinases

Share to Staurosporine

Source

Identifiers

PMID: 15178581
DOI: 10.1182/blood-2004-02-0712

Genes

FLT3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.PMID 15178581Read ↗

Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AMLSemantic proximity Read ↗

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).Semantic proximity Read ↗

Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptorSemantic proximity Read ↗

FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor developmentSemantic proximity Read ↗

FLT3 Mutations in Acute Myeloid Leukemia: Unraveling the Molecular Mechanisms and Implications for Targeted TherapiesSemantic proximity Read ↗

Targeting FLT3 mutations in AML: review of current knowledge and evidenceSemantic proximity Read ↗

Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.Semantic proximity Read ↗

Structural and functional alterations of FLT3 in acute myeloid leukemia.Semantic proximity Read ↗

Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.Semantic proximity Read ↗

Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AML.Semantic proximity Read ↗

FLT3 mutations in acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.